Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 100%Moderate 0 · 0%High 0 · 0%

Grades 3 and 4 adverse events · hospitalised individuals with COVID‐19 (moderate to severe disease)

Bamlanivimab showed no clear difference in adverse events: grades 3 and 4 by day 30 compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 1.27 [0.81, 1.98]
1 study · 314 participants
Low